HBM Holdings (HBM Holdings) ROCE % : 26.36% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. HBM Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was 26.36%.

HBM Holdings ROCE % Historical Data

The historical data trend for HBM Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings ROCE % Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-107.31

-142.99

-45.54

-67.79

16.52

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial						-55.22	-63.72	-67.94	6.65	26.36

HBM Holdings ROCE % Calculation

HBM Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	26.554	/	( ( (232.123 - 75.044)	+	(228.48 - 64.13) )	/ 2 )
	=	26.554	/	( (157.079	+	164.35)	/ 2 )
	=	26.554	/	160.7145
	=	16.52 %

HBM Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	42.608	/	( ( (223.513 - 64.607)	+	(228.48 - 64.13) )	/ 2 )
	=	42.608	/	( ( 158.906	+	164.35 )	/ 2 )
	=	42.608	/	161.628
	=	26.36 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

HBM Holdings (OTCPK:HBMHF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

HBM Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of HBM Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings (HBM Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (OTCPK:HBMHF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

02142:Hong Kong

Address

420 Fenglin Road, 12th Floor, Tower A, Fenglin International Plaza Phase II, Xuhui District, Shanghai, CHN, 200032

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.

HBM Holdings (HBM Holdings) Headlines

From GuruFocus

Harbour BioMed Announces Positive Profit Alert

By PRNewswire • 01-19-2024